Merck Sharp & Dohme LLC
Also filed as MERCK SHARP & DOHME LLC; Merck Sharp & Dohme Corp.; MERCK SHARP & DOHME CORP.
- Targets
- 5
- Filings
- 7
- Median premium
- 118%
- First filing
- Mar 4, 2021
- Latest filing
- Aug 18, 2025
Targets
| Company | Score before deal | Score now | Filings | Latest |
|---|---|---|---|---|
| Verona Pharma plc | 2 / 7 | — | 2 | Aug 18, 2025 |
| Harpoon Therapeutics, Inc. | — | — | 2 | Feb 8, 2024 |
| Imago BioSciences, Inc. | — | — | 1 | Dec 12, 2022 |
| ACCELERON PHARMA INC | 2 / 7 | — | 1 | Oct 12, 2021 |
| Pandion Therapeutics, Inc. | — | — | 1 | Mar 4, 2021 |
Deal filings
| Filed | Company | Form | Price | Premium |
|---|---|---|---|---|
| Aug 18, 2025 | Verona Pharma plc | DEFM14A | $13.38 | 100% |
| Aug 5, 2025 | Verona Pharma plc | PREM14A | $13.38 | 37.5% |
| Feb 8, 2024 | Harpoon Therapeutics, Inc. | DEFM14A | $23.00 | 118% |
| Jan 29, 2024 | Harpoon Therapeutics, Inc. | PREM14A | $23.00 | 118% |
| Dec 12, 2022 | Imago BioSciences, Inc. | SC TO-T | — | — |
| Oct 12, 2021 | ACCELERON PHARMA INC | SC TO-T | — | — |
| Mar 4, 2021 | Pandion Therapeutics, Inc. | SC TO-T | — | — |